tirzepatide patent expiration 2036 As the patents on semaglutide, a popular diabetes and anti-obesity drug that earned its Danish maker Novo Nordisk nearly USD 30 billion in FY25 alone, expire in nearly 100 countries next year Buyer Beware: Off-brand Ozempic, Zepbound

Individual susceptibility varies considerably, though the factors determining who will be affected remain incompletely understood

News provided by Eli Lilly and Company May 21, 2026, 06:45 ET In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving 30% weight loss, a level long associated with bariatric surgery Individuals with a baseline BMI 35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks At the 4 mg dose, reached with only a single escalation step, participants lost an average of 47.2 lbs (19.0%) at 80 weeks with a lower observed discontinuation rate due to adverse events vs

Safety considerations: Nausea is the most common side effect during dose escalation

Representative Michele Peas House Bill 4036 would set up clear safety standards for the compounding of GLP-1 medications in our state

Nanda N, Alphonse MP

I would like this item shipped VIA USPS to my address listed